Video content above is prompted by the following: Let’s conclude by discussing our perspectives on the future of CLL treatment. How do you envision the CLL patient experience evolving in the coming ...

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...

HOUSTON — Bruton's tyrosine kinase inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have revolutionized the ...

The treatment landscape of chronic lymphocytic leukaemia (CLL) was transformed when the small molecule drug ibrutinib ...

Early detection of blood cancers can significantly improve the chances of successful treatment. Some cancers can be detected ...

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic ...

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic ...

For most people, the word cancer implies that there’s a tumor or mass growing somewhere in the body. However, contrary to ...

RNA-sequencing has become a cornerstone in the study of gene expression, offering insights beyond mere mRNA transcript ...

Lifestyle Expert Jennifer Bonner discusses chronic lymphocytic leukemia, or CLL, and the exciting advancements in its ...

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.